Spectral AI (NASDAQ:MDAI) versus ADM Tronics Unlimited (OTCMKTS:ADMT) Head-To-Head Contrast

ADM Tronics Unlimited (OTCMKTS:ADMT) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ADM Tronics Unlimited and Spectral AI, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADM Tronics Unlimited	0	0	0	0	0.00
Spectral AI	1	0	2	0	2.33

Spectral AI has a consensus target price of $3.25, indicating a potential upside of 118.12%. Given Spectral AI’s stronger consensus rating and higher probable upside, analysts plainly believe Spectral AI is more favorable than ADM Tronics Unlimited.

Earnings & Valuation

This table compares ADM Tronics Unlimited and Spectral AI”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADM Tronics Unlimited	$3.20 million	1.69	-$120,000.00	N/A	N/A
Spectral AI	$19.65 million	2.33	-$7.57 million	($0.31)	-4.81

ADM Tronics Unlimited has higher earnings, but lower revenue than Spectral AI.

Institutional and Insider Ownership

67.1% of Spectral AI shares are held by institutional investors. 73.0% of ADM Tronics Unlimited shares are held by insiders. Comparatively, 30.7% of Spectral AI shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ADM Tronics Unlimited and Spectral AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADM Tronics Unlimited	-0.20%	-0.85%	-0.32%
Spectral AI	-41.11%	N/A	-35.64%

Risk & Volatility

ADM Tronics Unlimited has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Spectral AI beats ADM Tronics Unlimited on 8 of the 12 factors compared between the two stocks.

About ADM Tronics Unlimited

ADM Tronics Unlimited, Inc., through its subsidiaries, develops, manufactures, and sells electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. It operates through Chemical, Electronics, and Engineering segments. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. In addition, the company provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. Further, it offers water-based, adhesive and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Additionally, the company provides research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products, as well as medical electronic therapeutic technology. ADM Tronics Unlimited, Inc. was incorporated in 1969 and is headquartered in Northvale, New Jersey.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.